Cel Sci Corporation (CVM)

[G8TSTFL]

The big question is how much Geert is going to demand once Big Pharma comes a knocking?

There are tons of sites that show the top Pharma deals that go up to over 100B in the last few years.
From my research, the most recent apple to apple is in 2019 Amgen buying the psoriasis drug Otezla. This was a byproduct of the merger condition between Bristol-Myers Squibb and Celgene.
This drug had an estimated 2020 sales of about $2 billion (sound familiar) and then topping at $2.49 billion throughout 2028. Analyst put Otezla’s value at four to five times sales, or $8 billion to $10 billion.
The $13.4 billion price tag exceeded analysts’ estimates, indicating a fierce bidding war, even though the forced sale didn't put Celgene in a strong negotiating position. With current inflation, a 14B price tag.

This drug has patents expiring between 2023 and 2028, no significant applications other then psoriasis and tons of competition. So from my perspective, Amgen just needed another drug to show their shareholders they are doing something to increase revenue and their pipeline.

We all know Multikine’s portfolio and future is much brighter and once approved for lung, colon, breast and pancreatic cancers, it will make Ketruda’s 17.5 B yearly revenue look like play money. And whoever buys it, will eat into Merck’s Keytruda revenue, because you don’t need a cancer remission drug if there is no remission. That alone will make it a coveted ‘Golden Ring’.

So again, the big question is how much Geert is going to demand once Big Pharma comes a knocking?
I have my ideas, but they are so ‘Pie in the Sky’, that I feel stupid putting them out there.
Anyone else want to take a shot?